News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Barbara P. Yawn, MD, MSC

Articles by Barbara P. Yawn, MD, MSC

Asthma Expenditures in the United States Comparing 2004 to 2006 and 1996 to 1998

ByMatthew A. Rank, MD,Juliette T. Liesinger, BA,Jeanette Y. Ziegenfuss, PhD,Megan E. Branda, MS,Kaiser G. Lim, MD,Barbara P. Yawn, MD, MSC,James T. Li, MD, PhD,Nilay D. Shah, PhD

September 19th 2012

Increased expenditures in US asthma are driven by increased medication spending that are not offset by decreases in emergency department and hospital spending.

Development and Maintenance of a Community-Based Hepatitis C Registry

ByBarbara P. Yawn, MD, MSC,Lilliana Gazzuola, MD,Peter C. Wollan PhD,W. Ray Kim, MD, MBA

March 1st 2002

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

ByBarbara P. Yawn, MD, MSC,G. Richard Locke III, MD,Eva Lydick, PhD,Peter C. Wollan PhD,Susan L. Bertram, RN, MSN,Margary J. Kurland, RN

June 1st 2001

The Impact of a Simulated Immunization Registry on Perceived Childhood Immunization Status

ByBarbara P. Yawn, MD, MSC,Larry Edmonson, MPH,Lowell Huber, MACS,Gregory A. Poland, MD,Robert M. Jacobson, MD,Steven J. Jacobsen, MD, PhD

February 1st 1998

Latest Updated Articles

Development and Maintenance of a Community-Based Hepatitis C Registry
March 1st 2002
Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population
June 1st 2001
The Impact of a Simulated Immunization Registry on Perceived Childhood Immunization Status
February 1st 1998
Asthma Expenditures in the United States Comparing 2004 to 2006 and 1996 to 1998
September 19th 2012

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access